CINGW

Insider Trades

Actor	Holding Value	Last Transaction	Amount	Transaction Price	Current Price
Silva Raul R.EVP And CSO $213.4 shares Grant / ExerciseMar 31, 2026 $21.3K3.4k shares $6.21 --
Brams MatthewEVP And Chief Medical Officer --8.2k shares Grant / ExerciseMar 9, 2026 Disclosure amount unavailable1k shares -- --
Brams MatthewEVP And Chief Medical Officer --9.2k shares Grant / ExerciseMar 9, 2026 Disclosure amount unavailable4.5k shares -- --
Callahan Jennifer L.EVP And CFO --14k shares Grant / ExerciseMar 9, 2026 Disclosure amount unavailable6.4k shares -- --
Callahan Jennifer L.EVP And CFO --20.4k shares Grant / ExerciseMar 9, 2026 Disclosure amount unavailable15.3k shares -- --
Patel Nilay DahyabhaiEVP, CLO And CCO --3.4k shares Grant / ExerciseMar 9, 2026 Disclosure amount unavailable2.1k shares -- --

Trade CINGW

About Cingulate Inc.

Cingulate Inc. is a biopharmaceutical firm in the clinical development stage, dedicated to pioneering therapies for central nervous system and neurobiological conditions. Its leading investigational medicines are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), both designed to manage attention deficit/hyperactivity disorders (ADHD). Furthermore, the company is progressing CTx-2103 for the treatment of anxiety disorders. Established in 2012, Cingulate Inc. maintains its main office in Kansas City, Kansas, and also operates a facility in Morristown, New Jersey.

CEO: Shane J. Schaffer
IPO Date: Dec 8, 2021

Market Data

Open: $0.0385
High: $0.0385
Low: $0.0279
Volume: 1K
52W High: $0.0385
52W Low: $0.0279

Valuation

Market Cap: $188k
Enterprise Value: $8.9M

Financials

Free Cash Flow: $-17M
Revenue: $0
Net Income: $-22M
Cash: $11M
Debt: $8.8M

Events

EarningsAug 18

EPS est. -0.625